Navigating Treatment Decisions in Early-Stage Hormone Receptor-Positive Breast Cancer

Area of Science:

• Oncology
• Genomics
• Breast Cancer Research

Background:

• Early-stage hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treatment is complex due to numerous therapeutic options and varied patient responses.
• Tumor biology-guided care, particularly genomic assays, has enhanced risk stratification, identifying patients who benefit most from chemotherapy.
• Treatment-related and financial toxicity are significant concerns in managing this breast cancer subtype.

Purpose of the Study:

• To examine the challenges and controversies in managing early-stage hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
• To discuss the application of genomic assays in specific patient populations, such as premenopausal women with node-positive disease.
• To explore the evolving role of circulating tumor DNA (ctDNA) as a biomarker.

Main Methods:

• Review of current literature and clinical guidelines.
• Analysis of the utility of genomic assays in risk stratification.
• Evaluation of the prognostic and predictive value of circulating tumor DNA.

Main Results:

• Genomic assays are crucial for chemotherapy decision-making, but their use in premenopausal women with node-positive disease remains debated.
• Tailoring treatment for locally advanced tumors with favorable biology requires careful consideration of individual patient factors.
• Circulating tumor DNA shows promise as a biomarker for monitoring treatment response and predicting outcomes.

Conclusions:

• Personalized treatment strategies are essential for optimizing outcomes in hormone receptor-positive breast cancer.
• Further research is needed to clarify the optimal use of genomic assays and ctDNA in clinical practice.
• Balancing treatment efficacy with toxicity is a key consideration in managing this complex disease.